New Treatment Options for Atypical Hemolytic Uremic Syndrome with the Complement Inhibitor Eculizumab

ABSTRACT

Hemolytic uremic syndrome (HUS) is a disease characterized by microangiopathic hemolytic anemia, consumptive thrombocytopenia, and renal impairment. Often HUS is triggered by Shiga-like toxin- producing Escherichia coli. Less common is atypical HUS (aHUS), which is caused by defective complement control. aHUS is associated with mutations in genes encoding complement regulatory proteins in ~50% of patients with this syndrome. Furthermore, autoantibodies that inactivate to factor H have also been linked to the disease. Initial triggers include infections, use of endothelial-affecting drugs, malignancies, transplantation, and pregnancy. Advances in our understanding of the pathogenesis of atypical HUS suggest that complement inhibition may be used as treatment for the disease. We discuss the potential benefit of the complement inhibitor eculizumab for the treatment of aHUS.

KEYWORDS

Atypical hemolytic uremic syndrome - complement activation - complement inhibitor - eculizumab

REFERENCES

• 1 Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  361(17) 1676-1687
• 2 Noris M, Remuzzi G. Hemolytic uremic syndrome.  J Am Soc Nephrol. 2005;  16(4) 1035-1050
• 3 Jokiranta T S, Zipfel P F, Frémeaux-Bacchi V, Taylor C M, Goodship T J, Noris M. Where next with atypical hemolytic uremic syndrome?.  Mol Immunol. 2007;  44(16) 3889-3900
• 4 Atkinson J P, Goodship T H. Complement factor H and the hemolytic uremic syndrome.  J Exp Med. 2007;  204(6) 1245-1248
• 5 Loirat C, Noris M, Frémeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children.  Pediatr Nephrol. 2008;  23(11) 1957-1972
• 6 Thomas T C, Rollins S A, Rother R P et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.  Mol Immunol. 1996;  33(17-18) 1389-1401
• 7 Hillmen P, Hall C, Marsh J C et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.  N Engl J Med. 2004;  350(6) 552-559
• 8 Hillmen P, Young N S, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.  N Engl J Med. 2006;  355(12) 1233-1243
• 9 Shin J I, Lee J S. More on eculizumab for congenital atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  360(20) 2142-2143; author reply 2143
• 10 Nürnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  360(5) 542-544
• 11 Gruppo R A, Rother R P. Eculizumab for congenital atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  360(5) 544-546
• 12 Mache C J, Acham-Roschitz B, Frémeaux-Bacchi V et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.  Clin J Am Soc Nephrol. 2009;  4(8) 1312-1316
• 13 Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.  Am J Transplant. 2009;  9(11) 2644-2645
• 14 Davin J C, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.  Am J Kidney Dis. 2010;  55(4) 708-711